BioMarin Pharmaceutical Inc. (LON:0HNC)
 52.84
 +1.03 (1.99%)
  At close: Oct 31, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $776.13M USD in the quarter ending September 30, 2025, with 4.08% growth. This brings the company's revenue in the last twelve months to $3.09B, up 12.39% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm) 
 $3.09B
Revenue Growth 
 +12.39%
P/S Ratio 
 3.36
Revenue / Employee 
 $1.02M
Employees 
 3,040
Market Cap 
7.72B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% | 
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% | 
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% | 
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% | 
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
BioMarin Pharmaceutical News
- 5 days ago - BioMarin (BMRN) Achieves FDA Priority Review for Expanded Use of Palynziq - GuruFocus
 - 5 days ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
 - 6 days ago - Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharmaceutical Inc (BMRN) - GuruFocus
 - 6 days ago - Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday - The Motley Fool
 - 6 days ago - BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy - Nasdaq
 - 6 days ago - Wells Fargo Updates BioMarin Pharmaceutical (BMRN) Price Target | BMRN Stock News - GuruFocus
 - 6 days ago - BioMarin Pharmaceutical (BMRN) Stock Rises on Revenue Forecast - GuruFocus
 - 6 days ago - BioMarin Pharmaceutical (BMRN) Target Price Lowered by Stifel | BMRN Stock News - GuruFocus